{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-003250","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.002255+00:00","generated_at":"2026-06-27T12:58:18.431605+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi completes enrollment in Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis; top-line data expected Q2 2022","bullets":["PRISM trial enrolled ~360 subjects with severe pruritus and prurigo nodularis.","Trial evaluates Haduvio (nalbuphine ER) 162 mg versus placebo twice daily.","Primary endpoint: ≥4-point improvement in weekly mean WI-NRS at Week 14 vs baseline.","FDA previously granted Fast Track designation for nalbuphine ER in PN pruritus.","Top-line data expected in Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-003250","json":"https://secwatch.observer/filing/0001564590-22-003250.json","markdown":"https://secwatch.observer/filing/0001564590-22-003250.md","text":"https://secwatch.observer/filing/0001564590-22-003250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022003250/0001564590-22-003250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022003250/trvi-8k_20220201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:58:18.431605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}